Trial Profile
Registrational study of SD 101
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 15 May 2018
Price :
$35
*
At a glance
- Drugs Nelitolimod (Primary)
- Indications B-cell lymphoma; Follicular lymphoma; Haematological malignancies; Head and neck cancer; Lymphoma; Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Dynavax Technologies
- 15 May 2018 New trial record
- 08 May 2018 According to a Dynavax Technologies media release, this trial is anticipated to begin in 2018.